These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15609115)

  • 1. Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction.
    Antioch KM; Jennings G; Botti M; Chapman R; Wulfsohn V
    Eur J Health Econ; 2002; 3(1):26-39. PubMed ID: 15609115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
    Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ;
    Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis.
    Müllner M; Paulis M; Nikfardjam M; Domanovits H; Huber K
    Wien Klin Wochenschr; 1999 Jan; 111(1):37-41. PubMed ID: 10067269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eptifibatide and tirofiban: new preparations. Limited benefit.
    Prescrire Int; 2000 Oct; 9(49):135-8. PubMed ID: 11603412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting: an analysis based on the PRISM PLUS trial.
    Szucs TD; Meyer BJ; Kiowski W
    Eur Heart J; 1999 Sep; 20(17):1253-60. PubMed ID: 10454977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
    Ess SM; Szucs TD
    Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
    Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
    Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of the cost effectiveness of treatment of acute myocardial infarct with primary angioplasty and thrombolysis ].
    Golán L; Simek S; Linhart A; Cahlík T; Palecek T; Lubanda JC; Korínek J; Beran S; Aschermann M
    Vnitr Lek; 2003 Feb; 49(2):97-102. PubMed ID: 12728575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.
    Mahoney EM; Mehta S; Yuan Y; Jackson J; Chen R; Gabriel S; Lamy A; Culler S; Caro J; Yusuf S; Weintraub WS;
    Am Heart J; 2006 Jan; 151(1):219-27. PubMed ID: 16368322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
    J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
    Gianetti J; Gensini G; De Caterina R
    Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals.
    Coleman CI; McKay RG; Boden WE; Mather JF; White CM
    Clin Ther; 2006 Jul; 28(7):1054-62. PubMed ID: 16990084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
    Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
    J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The European Society of Cardiology (ESC) guidelines for percutaneous coronary interventions (PCI). Three case reports].
    Silber S; Richartz BM; Brilmayer M;
    Herz; 2006 Dec; 31(9):836-46, 848. PubMed ID: 17180646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
    Goel V; Naylor CD
    Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
    J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice.
    Menown I; Montalescot G; Pal N; Fidler C; Orme M; Gillard S
    Adv Ther; 2010 Mar; 27(3):181-91. PubMed ID: 20422473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.